WuXi AppTec Shares Rise After Strong Annual Results
By Amanda Lee
Shares of WuXi AppTec surged in Hong Kong after the Chinese pharmaceutical company reported strong annual profit and revenue growth.
The company's shares jumped as much as 9.8% to 112.80 Hong Kong dollars, equivalent to US$14.40, in Tuesday morning trade. The shares are on track for their biggest one-day percentage gain since July 2025.
The gains came after WuXi AppTec said Monday after market close that 2025 net profit more than doubled to 19.19 billion yuan, equivalent to US$2.79 billion. Revenue rose 16% to 45.46 billion yuan.
Based on the full-year results, Nomura estimated that WuXi AppTec's fourth-quarter sales rose 9.2% from a year earlier due to its WuXi Chemistry business division, said analyst Jialin Zhang in a note.
For this year, WuXi AppTec expects total revenue of between 51.3 billion yuan and 53.0 billion yuan, with revenue from continuing operations expected to grow 18% to 22%.
"We view the [2025] results and [2026] guidance as in-line with our estimates and quite impressive on a high base," Zhang said. The investment bank maintained a buy rating on Wuxi AppTec with a target price of HK$157.07.
Write to Amanda Lee at amanda.lee@wsj.com
(END) Dow Jones Newswires
March 24, 2026 00:03 ET (04:03 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
2 Undervalued Stocks to Buy Before They Rebound
United States